지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2008.4
- 수록면
- 255 - 260 (6page)
이용수
초록· 키워드
오류제보하기
Purpose: Tamoxifen has been prescribed as a very effective hormonal agent not only for the treatment of breast cancer, but also for the prevention of the disease. The development of resistance to tamoxifen is one of the most important obstacles to hormonal therapy of breast cancer. HER2 or EGFR expression has been reported to be associated with the development of tamoxifen resistance. This study was performed to evaluate the effect of HER2 and EGFR inhibition on tamoxifen resistance using tamoxifen-resistant breast cancer cells (T47D:A18/4-OHT cells).
Methods: Tamoxifen-resistant T47D:A18/4-OHT cells were established by long-term treatment of 1μM 4-hydroxytamoxifen on T47D:A18 human breast cancer cells. The effect of HER2 and EGFR inhibition was investigated by the use of a cell proliferation assay with treatment of trastuzumab, a monoclonal antibody to the extracellular domain of the human HER2 receptor, and ZD1839, an ERFR tyrosine kinase inhibitor.
Results: In contrast to T47D:A18 cells, T47D:A18/4-OHT cells showed estrogen-independent proliferation and partial regulation by treatment with tamoxifen. With a single treatment of trastuzumab or ZD1839, T47D:A18/4-OHT cell growth was reduced to 77.8% (P=0.15) or 74.4% (P=0.034) respectively, as compared to untreated cells. Combinational treatment with 1 nM estradiol resulted in a further reduction of T47D:A17 cell proliferation by 83.6% (P=0.002) for trastuzumab and 77.7% (P=0.047) for ZD1839, as compared to the single treatments.
Conclusion: Tamoxifen resistance could be partially regulated by inhibition of HER2 or EGFR in T47D:A18/4-OHT cells, especially in combination with a low dose of estradiol. This effect may provide an important clue to overcome tamoxifen resistance in the treatment of breast cancer.
Methods: Tamoxifen-resistant T47D:A18/4-OHT cells were established by long-term treatment of 1μM 4-hydroxytamoxifen on T47D:A18 human breast cancer cells. The effect of HER2 and EGFR inhibition was investigated by the use of a cell proliferation assay with treatment of trastuzumab, a monoclonal antibody to the extracellular domain of the human HER2 receptor, and ZD1839, an ERFR tyrosine kinase inhibitor.
Results: In contrast to T47D:A18 cells, T47D:A18/4-OHT cells showed estrogen-independent proliferation and partial regulation by treatment with tamoxifen. With a single treatment of trastuzumab or ZD1839, T47D:A18/4-OHT cell growth was reduced to 77.8% (P=0.15) or 74.4% (P=0.034) respectively, as compared to untreated cells. Combinational treatment with 1 nM estradiol resulted in a further reduction of T47D:A17 cell proliferation by 83.6% (P=0.002) for trastuzumab and 77.7% (P=0.047) for ZD1839, as compared to the single treatments.
Conclusion: Tamoxifen resistance could be partially regulated by inhibition of HER2 or EGFR in T47D:A18/4-OHT cells, especially in combination with a low dose of estradiol. This effect may provide an important clue to overcome tamoxifen resistance in the treatment of breast cancer.
목차
서론
방법
결과
고찰
결론
REFERENCES
참고문헌 (30)
참고문헌 신청
Early Breast Cancer Trialists' Collaborative Group / 2005 / Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials / Lancet 365:1687~1717
Fisher B / 1998 / Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study / J Natl Cancer Inst 90:1371~1388
Clarke R / 2003 / Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling / Oncogene 22:7316~7339
Benz CC / 1993 / Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu / Breast Cancer Res Treat 24:85~95
Nicholson RI / 1994 / Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy / Breast Cancer Res Treat 29:117~125
Fisher B / 1998 / Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study / J Natl Cancer Inst 90:1371~1388
Clarke R / 2003 / Antiestrogen resistance in breast cancer and the role of estrogen receptor signaling / Oncogene 22:7316~7339
Benz CC / 1993 / Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu / Breast Cancer Res Treat 24:85~95
Nicholson RI / 1994 / Epidermal growth factor receptor expression in breast cancer: association with response to endocrine therapy / Breast Cancer Res Treat 29:117~125
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Tamoxifen Resistance in Breast Cancer
Biomolecules & Therapeutics(구 응용약물학회지)
2012 .01
-
Radiation recall dermatitis induced by tamoxifen during adjuvant breast cancer treatment
Radiation oncology journal : ROJ
2014 .01
-
유방암 환자에서 술후 타목시펜요법의 의의
Annals of Surgical Treatment and Research
1999 .09
-
유방암 환자에서 Tamoxifen 치료에 의한 유방촬영술상의 변화
대한방사선의학회지
1997 .01
-
Genetic Polymorphisms of Tamoxifen Biotransformation Predictive of Tamoxifen Pharmacokinetics and its Clinical Implications in Patients with Breast Cancer
대한임상약리학회 학술대회
2007 .01
-
Del-1 promotes the proliferation and migration of tamoxifen-resistant MCF7 breast cancer cells
대한외과학회 학술대회 초록집
2017 .11
-
여성형 유방에 대한 타목시펜(Tamoxifen) 치료 8예
Annals of Surgical Treatment and Research
1995 .05
-
The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
Toxicological Research
2011 .06
-
Effects of mixed formulation of tamoxifen and blue honeysuckle on the pharmacokinetics profiles of tamoxifen after single oral administration
대한한의학회지
2019 .12
-
Effects of Tamoxifen on Bone Mineral Turnover in women with Breast Cancers
대한외과학회 학술대회 초록집
1997 .05
-
타목시펜 내성 유방암세포(T47D : A18/4-OHT)에서 trastuzumab과 ZD1389의 효과
대한외과학회 학술대회 초록집
2004 .10
-
[Poster] Effect of Epigenetic Agents and Tamoxifen on Apoptosis of Breast Cancer Cell Lines
대한외과학회 학술대회 초록집
2011 .11
-
Synergistic Effects of Tamoxifen and Tranilast on VEGF and MMP-9 Regulation in Cultured Human Breast Cancer Cells
Asian Pacific journal of cancer prevention : APJCP
2013 .01
-
신장 근위세뇨관세포에서 tamoxifen의 항산화 효과
Laboratory Animal Research
2003 .06
-
유방암 환자에서 c-erbB-2 과발현이 Tamoxifen의 치료 효과에 미치는 영향
Annals of Surgical Treatment and Research
2003 .08
-
Effect of the Single Oral Combination Treatment of Tamoxifen with Gamisoyo-san on the Pharmacokinetics Profiles of Tamoxifen
동의생리병리학회지
2020 .08
-
유방암 수술환자가 Tamoxifen복용기간 중 발생하는 FSH와 E2의 수치 변화
핵의학기술
2010 .01
-
유방암 환자에서 타목시펜의 골 대사 효과
Annals of Surgical Treatment and Research
1998 .11
-
여성형유방 환자에서 타목시펜 치료 효과
Journal of Breast Disease
2019 .01
이 논문의 저자 정보
이 논문과 함께 이용한 논문
유방암 환자의 타목시펜 사용 후 자궁내막에 발생한 암병변 4예
홍수정
,
이정선
,
김희정
외 4명
대한외과학회 학술대회 초록집
2005
.10
유방암 환자의 술 후 타목시펜 복용에 의해 발생한 각막혼탁
류동희
,
윤효영
,
유동기
외 2명
Annals of Surgical Treatment and Research
2006
.05
Impact of pretransplant rituximab induction on highly sensitized kidney recipients : comparison with non-rituximab group
Young Hae Song
,
Kyu Ha Huh
,
Yu Seun Kim
외 6명
Annals of Surgical Treatment and Research
2012
.06
경피적 심낭배액술과 Trastuzumab 단독요법으로 치료한 심낭압전을 동반한 유방암의 심막전이
문형곤
,
정은정
,
박순태
외 7명
Annals of Surgical Treatment and Research
2008
.08
[Free Paper] Impact of Pretransplant Rituximab Induction on Kidney Graft in Highly Sensitized Recipients
송영해
,
허규하
,
김유선
외 4명
대한외과학회 학술대회 초록집
2011
.11
최근 본 자료
댓글(0)
0
UCI(KEPA) : I410-ECN-0101-2013-514-002693303